European Union

EPO Patent Publication: Blood Brain Barrier Penetrant AAV Capsids

The European Patent Office (EPO) has published a patent application (EP2026030714A1) concerning pharmaceutical compositions containing blood-brain barrier penetrant AAV capsids. The publication date is March 18, 2026, and it covers various designated states within the European Union.

EPO Patent Granted for Peptides and Their Use

The European Patent Office (EPO) has granted patent EP3439682B1 for hypersensitive response elicitor-derived peptides and their use. The patent is effective March 18, 2026, and covers specific peptide sequences and their applications.

EPO Patent Grant EP3504318B1: Improving Methyltransferase Activity

The European Patent Office has granted patent EP3504318B1, titled 'Method of Improving Methyltransferase Activity'. This patent relates to biotechnology and is designated for multiple European states.

Immunotherapy Patent Grant EP3465203B1

The European Patent Office (EPO) has published patent grant EP3465203B1 concerning methods of immunotherapy. The patent, listing Rajiv Khanna and Corey Smith as inventors, was published on March 18, 2026. This grant is part of the EPO's ongoing dissemination of intellectual property information.

EPO Patent EP3265098B1: Modulating Mecp2 Expression Compositions

The European Patent Office has granted patent EP3265098B1 for compositions intended to modulate Mecp2 expression. This patent, effective March 18, 2026, covers specific inventions related to biotechnology and pharmaceutical applications.

EPO Patent Application: Methods for Selectively Targeting Neuronal Pathways

The European Patent Office has published patent application EP2026030664A1 concerning methods for selectively targeting neuronal pathways. The publication date is March 18, 2026. The designation of the inventor has not yet been filed.

EPO Patent Granted for Human Tissue Derived Compositions

The European Patent Office (EPO) has granted patent EP3474869B1 for human tissue derived compositions and their uses. The patent was published on March 18, 2026, and covers various applications in biotechnology and medicine.

EPO Patent Grant EP3538656B1 for Reducing ATXN3 Expression

The European Patent Office has granted patent EP3538656B1 for compounds designed to reduce ATXN3 expression. This patent covers specific chemical compounds and their use in treating conditions related to ATXN3. The grant is effective March 18, 2026.

EPO Patent Grant EP3560519B1: Virus AAV/IGF2 Genetic Treatment Method

The European Patent Office has granted patent EP3560519B1 for a virus AAV/IGF2 genetic treatment method and its use in protein misfolding-related diseases. The patent was published on March 18, 2026, and covers specific genetic treatment applications.

EPO Patent Publication EP2026029704A1: Dumbbell-shaped DNA vectors

The European Patent Office has published patent application EP2026029704A1 concerning dumbbell-shaped DNA vectors. The publication date is March 18, 2026, and it falls under the C12N IPC classification for biotechnology. No inventors have been designated yet.